BackgroundConstipation is a common condition in patients with neurodegenerative parkinsonism, including Parkinson’s disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). Chronic constipation negatively impacts quality of life and decrease the absorption of antiparkinsonian drugs. Linaclotide (guanylate cyclase C agonist) and prucalopride (selective 5-HT4 receptor agonist) are emerging effective drugs for the management of chronic idiopathic constipation (CIC). To date, neither of these drugs has been tested in controlled trials in parkinsonism patients and their efficacy is unknown in this population.
展开▼
